Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

Blood cancers such as leukaemia and lymphoma
Inherited genetic disorders including thalassemia and sickle cell disease
Neurological conditions such as cerebral palsy and brain injury
Immune deficiencies and metabolic disorders
Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

Cerebral Palsy
Thalassemia
Leukaemia
HSV Encephalitis
Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

Families gain access to 1,000,000+ stored cord blood units across the network
Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

Order now Find out more

FamiCord Group releases

Patients

7800+

Expand table
No.	Source	Source type	Diagnosis	Medical sector	Year of application	Therapy	Country	Age of the recipient
8401	Apheresis	Autologous	Neuroblastoma	Hematology	2013	Standard Therapy	Germany	1
8402	Apheresis	Allogeneic	No Data	Hematology	2013	Standard Therapy	Germany	51
8403	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2013	Standard Therapy	Germany	60
8404	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2013	Standard Therapy	Germany	60
8405	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2013	Standard Therapy	Germany	60
8406	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2013	Standard Therapy	Germany	68
8407	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2013	Standard Therapy	Germany	73
8408	Apheresis	Autologous	Plasmacytoma	Hematology	2013	Standard Therapy	Germany	62
8409	Apheresis	Allogeneic	Primary Central Nervous System Lymphoma	Hematology	2013	Standard Therapy	Germany	52
8410	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2013	Standard Therapy	Germany	43
8411	Apheresis	Allogeneic	Primary Myelofibrosis, Second Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	60
8412	Apheresis	Allogeneic	Primary Osteomyelofibrosis	Hematology	2013	Standard Therapy	Germany	59
8413	Apheresis	Allogeneic	T-Cell Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	61
8414	Apheresis	Allogeneic	T-Cell Non-Hodgkin Lymphoma	Hematology	2013	Standard Therapy	Germany	45
8415	Apheresis	Autologous	Teratocarcinoma	Hematology	2013	Standard Therapy	Germany	49
8416	Apheresis	Autologous	Testicular Cancer Relapse	Hematology	2013	Standard Therapy	Germany	27
8417	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2012	Experimental Therapy	Poland	19,7
8418	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2012	Experimental Therapy	Poland	7,1
8419	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2012	Experimental Therapy	Poland	4,3
8420	Cord Blood	Allogeneic – Related	Acute Lymphoblastic Leukemia	Hematology	2012	Standard Therapy	Germany	2
8421	Cord Blood	Allogeneic – Related	Beta Thalassemia	Hematology	2012	Standard Therapy	Germany	14
8422	Cord Blood	Autologous	Brain Damage	Neurology	2012	Experimental Therapy	Germany	3
8423	Cord Blood	Autologous	Cerebral Palsy	Neurology	2012	Experimental Therapy	Portugal	3
8424	Cord Blood	Allogeneic – Related	Myelodysplastic Syndrome	Hematology	2012	Standard Therapy	Hungary	3
8425	Cord Blood	Allogeneic – Related	T-Cell Acute Lymphoblastic Leukemia	Hematology	2012	Standard Therapy	Turkey	4,1
8426	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2012	Standard Therapy	Turkey	6,7
8427	Cord Blood	Allogeneic – Related	Thalassemia Major, Acute Lymphoblastic Leukemia	Hematology	2012	Standard Therapy	Turkey	3,6
8428	Cord Blood	Autologous	Typ-1-Diabetes	Endocrinology	2012	Experimental Therapy	Germany	5
8429	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2012	Standard Therapy	Germany	64
8430	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2012	Standard Therapy	Germany	75
8431	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2012	Standard Therapy	Germany	55
8432	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2012	Standard Therapy	Germany	56
8433	Bone Marrow	Allogeneic	Myelodysplastic Syndrome Refractory Anemia With Blast Excess	Hematology	2012	Standard Therapy	Germany	70
8434	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2012	Standard Therapy	Germany	18
8435	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	42
8436	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	43
8437	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	60
8438	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	39
8439	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	62
8440	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	55
8441	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2012	Standard Therapy	Germany	17
8442	Apheresis	Allogeneic	Acute Myeloid Leukemia – Relapse	Hematology	2012	Standard Therapy	Germany	48
8443	Apheresis	Allogeneic	Acute Myeloid Leukemia – Relapse	Hematology	2012	Standard Therapy	Germany	46
8444	Apheresis	Allogeneic	Acute Myeloid Leukemia – Relapse	Hematology	2012	Standard Therapy	Germany	68
8445	Apheresis	Allogeneic	Acute Myeloid Leukemia (High Risk)	Hematology	2012	Standard Therapy	Germany	57
8446	Apheresis	Allogeneic	B-Cell Acute Lymphoblastic Leukemia	Hematology	2012	Standard Therapy	Germany	47
8447	Apheresis	Allogeneic	B-Cell Acute Lymphoblastic Leukemia	Hematology	2012	Standard Therapy	Germany	43
8448	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma – Relapse	Hematology	2012	Standard Therapy	Germany	70
8449	Apheresis	Autologous	Central Nervous System Non-Hodgkin Lymphoma	Hematology	2012	Standard Therapy	Germany	54
8450	Apheresis	Autologous	Cerebral Diffuse Large B-Cell Lymphoma-Relapse	Hematology	2012	Standard Therapy	Germany	55
8451	Apheresis	Autologous	Diffuse Large B-Cell Non-Hodgkin-Lymphoma	Hematology	2012	Standard Therapy	Germany	54
8452	Apheresis	Autologous	Extragonadal Germ Cell Tumor	Hematology	2012	Standard Therapy	Germany	59
8453	Apheresis	Autologous	Follicular Lymphoma	Hematology	2012	Standard Therapy	Germany	54
8454	Apheresis	Autologous	Follicular Lymphoma	Hematology	2012	Standard Therapy	Germany	57
8455	Apheresis	Autologous	Follicular Lymphoma-Relapse	Hematology	2012	Standard Therapy	Germany	59
8456	Apheresis	Autologous	Lymphoblastic B-Cell Non-Hodgkin-Lymphoma	Hematology	2012	Standard Therapy	Germany	52
8457	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2012	Standard Therapy	Germany	61
8458	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2012	Standard Therapy	Germany	52
8459	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2012	Standard Therapy	Germany	57
8460	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2012	Standard Therapy	Germany	55
8461	Apheresis	Autologous	Medulloblastoma	Hematology	2012	Standard Therapy	Germany	42
8462	Apheresis	Autologous	Morbus Hodgkin-Relapse	Hematology	2012	Standard Therapy	Germany	27
8463	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	51
8464	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	60
8465	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	52
8466	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	71
8467	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	61
8468	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	53
8469	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	55
8470	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	70
8471	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	46
8472	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	64
8473	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	56
8474	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	68
8475	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	48
8476	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	59
8477	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	62
8478	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	72
8479	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	50
8480	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	60
8481	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	65
8482	Apheresis	Autologous	Multiple Myeloma	Hematology	2012	Standard Therapy	Germany	67
8483	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2012	Standard Therapy	Germany	49
8484	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2012	Standard Therapy	Germany	69
8485	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2012	Standard Therapy	Germany	62
8486	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2012	Standard Therapy	Germany	57
8487	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2012	Standard Therapy	Germany	62
8488	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2012	Standard Therapy	Germany	57
8489	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2012	Standard Therapy	Germany	44
8490	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2012	Standard Therapy	Germany	43
8491	Apheresis	Allogeneic	Osteomyelofibrosis	Hematology	2012	Standard Therapy	Germany	61
8492	Apheresis	Autologous	Plasmablastic Lymphoma	Hematology	2012	Standard Therapy	Germany	54
8493	Apheresis	Autologous	Plasmacytoma	Hematology	2012	Standard Therapy	Germany	69
8494	Apheresis	Autologous	Testicular Cancer Relapse	Hematology	2012	Standard Therapy	Germany	36
8495	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2011	Experimental Therapy	Poland	17,2
8496	Cord Blood	Allogeneic – Related	Acute Lymphoblastic Leukemia	Hematology	2011	Standard Therapy	Poland	5
8497	Cord Blood	Allogeneic – Related	Acute Lymphoblastic Leukemia	Hematology	2011	Standard Therapy	UK	8
8498	Cord Blood	Allogeneic – Related	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Hungary	2
8499	Cord Blood	Autologous	Brain Damage	Neurology	2011	Experimental Therapy	Germany	3
8500	Cord Blood	Autologous	Brain Damage	Neurology	2011	Experimental Therapy	Germany	7

Page 85 of 89 1 83 84 85 86 87 89

Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

100% infusion success rate

For samples released for transplant.

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

Expand table
Sample release date	Medical condition	Recipient relationship	Age of the recipient	Unit volume	Medical center	Country
2005.11	Thalassemia	Allogeneic (Sibling)	4 Years	144ml	Mount Vernon Hospital	Singapore
2005.11	Leukaemia	Allogeneic (Sibling)	Restricted	Restricted	Stem Cells and Immunology Department, Birmingham	UK
2007.02	Thalassemia	Allogeneic (Sibling)	7 Years	76ml	Kinderlink der Tu Munchen	Germany
2009.08	Cerebral Palsy	Autologous (Self)	3 Years	51ml	Duke University, North Carolina	USA
2010.01	Cerebral Palsy	Autologous (Self)	3 Years	81ml	Duke University, North Carolina	USA
2013.10	Thalassemia	Allogeneic (Sibling)	5 Years	58ml	Catherine Lewis Centre, Hammersmith	UK
2014.01	Leukaemia	Allogeneic (Sibling)	4 Years	71ml	Medizinische Hochschule, Hanover	Germany
2014.05	Cerebral Palsy	Autologous (Self)	1 year	68ml	Duke University, North Carolina	USA
2014.06	HSV Encephalitis & NMDA Receptor Antibody Virus	Autologous (Self)	2 Years	57ml	Duke University, North Carolina	USA
2014.08	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	3 Months	39ml	Duke University, North Carolina	USA
2015.02	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	6 Months	53ml	Duke University, North Carolina	USA
2015.03	Severe Combined Immune Deficiency	Autologous (Self)	3 Months	74ml	Duke University, North Carolina	USA
2015.03	Sickle Cell Disease	Allogeneic (Sibling)	2 .5 Years	57ml	BLK Hospital, New Delhi	India
2015.11	Thalassemia	Allogeneic (Sibling)	12 Years	87ml	Children’s Hospital of Pittsburgh of UPMC	USA
2016.03	Cerebral Palsy	Allogeneic (Sibling)	6 Years	101ml	Duke University, North Carolina	USA
2017.04	Lymphoblastic Leukaemia (^1)	N/A (Identical twin girls)	Restricted	125ml	Bambin Gesu Childrens’ Hospital, Rome	Italy
2017.06	Cerebral Palsy	Autologous (Self)	7 Years	82ml	Duke University, North Carolina	USA
2017.06	Cerebral Palsy	Autologous (Self)	3.4 Years	132ml	Duke University, North Carolina	USA
2018.03	Autism	Autologous (Self)	5.4 Years	73ml	Duke University, North Carolina	USA
2018.03	Cerebral Palsy	Autologous (Self)	3.4 years	132ml	Duke University, North Carolina	USA
2019.06	Cerebral Palsy	Allogeneic (Sibling)	3 Years	104ml	Duke University, North Carolina	USA
2022.02	Cerebral Palsy	Allogeneic (Sibling)	11 Years	185ml	Duke University, North Carolina	USA
2023.08	Cerebral Palsy	Allogeneic (Sibling)	3 Years	46ml	Duke University, North Carolina	USA
2024.01	Thalassaemia	Allogeneic (Sibling)	8 Years	45ml	Cincinnati Children’s Hospital Medical Center	USA